Exhibits
S-4
from S-4
170 pages
S-4
10/14/11
EX-4.2
from S-4
5 pages
Supplemental Indenture
10/14/11
EX-4.3
from S-4
5 pages
Second Supplemental Indenture
10/14/11
EX-4.4
from S-4
5 pages
Third Supplemental Indenture
10/14/11
EX-4.5
from S-4
6 pages
Fourth Supplemental Indenture
10/14/11
EX-4.6
from S-4
6 pages
Fifth Supplemental Indenture
10/14/11
EX-4.7
from S-4
6 pages
Sixth Supplemental Indenture
10/14/11
EX-4.8
from S-4
8 pages
Seventh Supplemental Indenture
10/14/11
EX-4.11
from S-4
6 pages
First Supplemental Indenture
10/14/11
EX-4.12
from S-4
6 pages
Second Supplemental Indenture
10/14/11
EX-4.13
from S-4
8 pages
Third Supplemental Indenture
10/14/11
EX-4.16
from S-4
6 pages
First Supplemental Indenture
10/14/11
EX-4.17
from S-4
6 pages
Second Supplemental Indenture
10/14/11
EX-4.18
from S-4
8 pages
Third Supplemental Indenture
10/14/11
EX-5
from S-4
9 pages
Opinion of Skadden, Arps, Slate, Meagher & Flom Llp
10/14/11
EX-12
from S-4
~5
pages
Statement Regarding Computation of Ratio of Earnings to Fixed Charges
10/14/11
EX-21
from S-4
2 pages
Subsidiaries of the Registrant
10/14/11
EX-23.1
from S-4
1 page
Consent of Independent Registered Public Accounting Firm
10/14/11
EX-23.2
from S-4
1 page
Consent of Independent Registered Public Accounting Firm
10/14/11
EX-23.3
from S-4
1 page
Consent of Independent Registered Public Accounting Firm
10/14/11
EX-25.1
from S-4
7 pages
Statement of Eligibility of Trustee, Indenture for 7.00% Senior Notes Due 2020
10/14/11
EX-25.2
from S-4
7 pages
Statement of Eligibility of Trustee, Indenture for 7% Senior Notes Due 2019
10/14/11
EX-25.3
from S-4
7 pages
Statement of Eligibility of Trustee, Indenture for 7 1/4% Senior Notes Due 2022
10/14/11
EX-99.1
from S-4
21 pages
Letter of Transmittal Endo Pharmaceuticals Holdings Inc
10/14/11
EX-99.2
from S-4
4 pages
Endo Pharmaceuticals Holdings Inc
10/14/11
EX-99.3
from S-4
2 pages
Endo Pharmaceuticals Holdings Inc
10/14/11
